Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development.
Pharma power play hinges mostly on the initial R&D race to market dominance. Research innovation and investment has enticing potential. The Pharmaceutical industry pipeline was noted to have seen a 5% year on year increase in the first quarter of 2016 1 . Just under 70% of that pipeline is covered by the therapy areas of oncology, infectious diseases and central nervous system disorders. The same report noted that the price to bring a single novel drug to market rested at around $2.6 billion in 2015. Full Article »
Japanese pharmaceutical giant Eisai has launched a new epilepsy drug in Europe following approval by the European Commission.
Discovered and developed in the United Kingdom, Fycompa® (perampanel) is an important new addition to the treatment of epilepsy in Europe as it has efficacy in difficult-to-treat patients with uncontrolled partial o Full Video »
Diabetes is a global threat. Researchers estimate that 26.6 million people in the Middle East and North Africa currently have diabetes. Six countries in the region are among the top 10 globally with the highest prevalence of diabetes. In this interview Professor Peter Schwarz, Head of Department of Prevention and Care of Diabetes University Full Podcast »
Why are IO therapies buzzing today? If we look back at the history of cancer treatment, the survival rate was measured in months, which according to oncologists was a lot back then, because the mortality rate in most cancers was 100%. Most traditional chemotherapies were not well tolerated, because they would kill both cancerous and healthy cells, leading to major side effects such as loss of hair, nausea and vomiting, and risk of infection. Survival was sometimes better, but not much better, depending on the type of cancer and the patient's own genetic and physiological make-up. The big advantage of IO therapies is that they can target specific receptors on the cancer cells and destroy them while leaving the healthy cells alone. This will also help reduce some of the traditional side effects when healthy cells are destroyed. Full Column »
Ahead of this year’s Early Access Programmes Europe conference, Pharma IQ expands its regulatory handbook to develop the industry’s awareness of the various compliance requirements that surround the implementation of these programmes Full Whitepaper »